Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of COVID-19. The main receptor of SARS-CoV-2, angiotensin I converting enzyme 2 …

Patients with cancer have been disproportionately affected by the COVID-19 pandemic.
This effect has included the adverse outcomes in patients with cancer who develop COVID-19, …

Despite rare cancers accounting for 25% of adult tumors 1 , they are difficult to study due to
the low disease incidence and geographically dispersed patient populations, which has …

Evaluating the potential role of COVID-19 treatments in patients with cancer in a large
observational study, there was no statistically significant 30-day all-cause mortality benefit with …

Background— Plasminogen activator inhibitor-1 (PAI-1) regulates fibrinolysis and has been
reported to be an independent risk factor for ischemic cardiovascular events. This study …

Circadian variation in plasminogen activator inhibitor-1 (PAI-1) production likely contributes
to increased risk of myocardial infarction and decreased efficacy of thrombolytic therapy …

Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of plasminogen activation
and likely plays important roles in coronary thrombosis and arteriosclerosis. Tumor necrosis …

Importance Non-Hispanic Black individuals experience a higher burden of COVID-19 than
the general population; hence, there is an urgent need to characterize the unique clinical …

Mammalian class II major histocompatibility (MHCII) proteins bind peptide antigens in
endosomal compartments of antigen-presenting cells. The nonclassical MHCII protein HLA-DM …